Articles by William Looney - Pharmaceutical Executive


Articles by William Looney

HBA Woman of the Year 2012

Apr 1, 2012

Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens.

Emerging Markets: Setting a New Agenda

Apr 1, 2012

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

IP: Time for a Reset?

Apr 1, 2012

Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.

Novartis: LEADing in Emerging Markets

Mar 12, 2012

With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.

The Maestros

Mar 1, 2012

Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.

Brand Success: It's Not Serendipity

Feb 1, 2012

A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.

Pharma 2012: Hard Times Before the Harvest

Jan 1, 2012

The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.

Was 2011 the End of the Beginning?

Dec 1, 2011

The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.

The Medicines Adherence Challenge

Dec 1, 2011

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma — but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.


Click here